-

04:02:28 AM

SCPH Stock News

SCPH - scPharmaceuticals Inc

11/22/22 8:01 AM

Nasdaq : SCPH

offeringlow float

scPharmaceuticals Announces Pricing of $50 Million Public Offering

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

RHEA-AI

neutral

11/09/22 4:05 PM

Nasdaq : SCPH

earningslow float

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced FDA marketing approval of FUROSCIX ® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Entered into a secured debt financing agreement for up to $100 million with funds managed by

RHEA-AI

neutral

11/02/22 8:00 AM

Nasdaq : SCPH

conferenceslow float

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

RHEA-AI

neutral

10/26/22 8:00 AM

Nasdaq : SCPH

earningslow float

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

RHEA-AI

neutral

10/10/22 9:41 AM

Nasdaq : SCPH

fda approvallow float

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on

RHEA-AI

neutral

10/10/22 8:05 AM

Nasdaq : SCPH

low float

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused

RHEA-AI

neutral

10/10/22 8:00 AM

Nasdaq : SCPH

fda approvallow float

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on

RHEA-AI

neutral

09/30/22 8:00 AM

Nasdaq : SCPH

low float

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on

RHEA-AI

neutral

09/01/22 8:00 AM

Nasdaq : SCPH

conferenceslow float

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs,

RHEA-AI

neutral

08/09/22 7:00 AM

Nasdaq : SCPH

earningslow float

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of FUROSCIX ® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of an anticipated Q4 2022 launch of FUROSCIX, if approved Ended Q2 with cash, cash equivalents,

RHEA-AI

neutral

SCPH Data

IndustryMedicinal and Botanical Manufacturing
Websitewww.scpharmaceuticals.com
CeoJohn Tucker
Security namescPharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees27
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
Address2400 District Ave Ste 310
StateMassachusetts
CityBurlington
Zip01803-5239
CountryUS
Phone16175170730

About scPharmaceuticals Inc

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA.